SIGN UP FOR UPDATES!
Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
ENGLEMED
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BOOKS AND GIFTS THIS WAY!
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
SEARCH THIS SITE
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
FreeDigitalPhotos
www.freedigitalphotos.net
FreeWebPhotos
www.freewebphoto.com
FROM OUR NEWS FEEDS
Warning on growing palliative care needs
Thurs May 23rd - The number of people needing palliative care globally is set to double in the next 40 years, according to a new projection. More
Red wine compound investigated for hypertension care
Thurs May 23rd - A compound produced by fruits in response to injury or attack could hold the key for to new treatments for hypertension, researchers report today. More
RECENT COMMENTS
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote:
https://epidemicj17.imascientist.org.uk/2017/06/21... on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
On 12/03/2017 Steph wrote:
The photo you have paired with this article is its... on 'Fat shaming' limits...
OUR CLIENTS
THIS WEEK'S STORIES
ENGLEMED HEALTH NEWS

Liquid biopsy could help to halt metastatic cancer

Thursday May 16th, 2019

A liquid biopsy could help to identify cancer patients who are at risk of their disease spreading, a conference heard yesterday (15 May 2019).

Researchers at The Royal Marsden NHS Foundation Trust, London, told delegates at the EACR-ESMO joint conference that ctDNA could be used to monitor treatment response in patients with locally advanced rectal cancer.

This would allow the treatment to be adapted or changed early to prevent the disease spreading.

The research team analysed liquid biopsies from 47 patients at The Royal Marsden who had localised rectal cancer. Blood samples were taken before, during and after patients had completed treatment with combined chemotherapy and radiotherapy (CRT), and after surgery.

The researchers detected ctDNA in 74% of patients pre-treatment, 21% of patients mid-way through CRT, 21% after CRT and 13% after surgery. They found that ctDNA results at the end of CRT were associated with tumour response to CRT as shown on MRI scans.

In a follow up, which took place over a median of just over 2 years, they found ctDNA results were consistent with occurrences of cancer spreading outside of the rectum, while patients for whom ctDNA persisted throughout treatment were more likely to develop metastatic disease sooner.

Lead author Dr Shelize Khakoo, medical oncologist at The Royal Marsden NHS Foundation Trust said: "If we can predict early on who will go on to develop metastatic disease, we might be able to tailor treatment by making it more intense or trying an alternative."

Co-lead author Professor David Cunningham OBE, consultant medical oncologist at The Royal Marsden NHS Foundation Trust said the results suggest that liquid biopsies can provide an accurate method of establishing the cancer's activity throughout the body.

"Importantly what this study showed, which has not yet been explored, is that persistence of ctDNA mid-way through treatment could be an early indicator of the cancer's potential to spread,” he said.

“Using this measure, along with MRI scans, we can offer a more personalised treatment approach for patients."

Tags: Cancer | Pharmaceuticals | UK News

Printer friendly page Printer friendly page

Comment on this article:

Name:
Email:
Comment:
<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)
CATEGORIES